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and severe (n = 25; 31%). CONCLUSION: Constipation was
reported by approximately 25% of the hospice patients, a third
of whom rated their constipation as severe. A substantial number
of hospice patients may require aggressive management of con-
stipation. This information may be useful as a process indicator
of quality of care.
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OBJECTIVE: Assess knowledge and care seeking behaviors
for gastro-esophageal reﬂux disease via a population-based
approach. Identify variations in knowledge, attitude, and care
seeking patterns between racial groups, while also investigating
socio-economic disparities. METHODS: A questionnaire based
upon previous work (Srinivansin, J Clin Gastro) was developed
to assess knowledge, attitudes, and care seeking patterns for
GERD and was translated into Chinese and Spanish. We worked
with community and faith-based leaders to identify events for
data collection. Four ethnic groups (White, Black, Asian, His-
panic) were compared. All descriptive and multivariate analyses
were done using SAS 9.1. RESULTS: Although Hispanics had the
highest prevalence rate for GERD, their familiarity with the
condition was lower (61.2%), compared to Whites (68.9%) and
Blacks (63.7%); Asians were the least familiar with GERD
(44.6%) (P < 0.0001). There was a positive correlation between
increased education level and awareness for GERD (P < 0.0001).
In general, Whites were the most likely to recognize GERD
symptoms and behaviors to control GERD, while Asians were
the least likely. Blacks and Hispanics were more likely to go to
the Emergency Room for severe heartburn compared to Asians
and Whites (P < 0.0001). Asians were least likely to go see a
doctor when presented with a complication of heartburn
(P < 0.0001). A total of 40.8% of Asians and 35.5% of Hispan-
ics indicated that cost and the lack of health insurance would
prevent them from seeing a doctor, higher rates than Whites and
Blacks (P = 0.0073). CONCLUSION: Minorities lack an equal
understanding of GERD, compared to Whites. Asians were par-
ticularly inaccurate in assessing symptoms for GERD and were
least likely to see a doctor. Further research should focus on
improving minority understanding of GERD symptoms and at
what point to consult a physician. The impact of cost and lack of
insurance on care seeking behaviors amongst Hispanics and
Asians should also be examined.
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OBJECTIVE: To examine pharmacy costs of a Prior Authoriza-
tion (PA) on lubiprostone for elderly chronic constipation (CC)
patients in a Medicare Part-D plan. METHODS: Cost impact of
PA was calculated by estimating annual pharmacy cost differ-
ences with PA (PA administration costs + medication costs) and
without PA (medication costs only). Model inputs included pub-
lished estimates of CC prevalence; lubiprostone utilization from
IMS Health, 2007; average PA approval rate, PA costs and
co-payment from payer interviews; and lubiprostone wholesale
acquisition costs. Annual medication costs in both scenarios
included costs and utilization of lubiprostone less co-payment,
assuming third-tier placement for lubiprostone. All previously
rejected prescriptions were assumed to be approved after lifting
PA, resulting in 21.24% increase in prescription volume. Sensi-
tivity analyses were performed on PA cost, PA approval rate,
and expected increase in prescription volume after lifting PA.
RESULTS: CC prevalence was 14.7%, of which 1.14% were
lubiprostone users. For a 1-million member plan, this resulted in
1264 PA requests costing $27 each. Annual cost of PA adminis-
tration was $34,130. PA approval rate for the elderly was 77.7%
(or 982 approved users). Average number of ﬁlls per person per
year was 3.8. A 30-day lubiprostone prescription costed $28.40
($86.40 WAC-$60 co-payment + $2 dispensing fee). Drug costs
were $105,997, resulting in total annual cost with PA of
$140,127. Total annual costs without PA were $128,506, based
on an additional 209 users, resulting in annual savings of
$11,621. Sensitivity analyses indicated break even scenarios from
removing PA on lubiprostone when cost per PA > $17.81 or PA
approval rate > 69.18%, or expected increase in prescriptions
from lifting PA < 32.20%. CONCLUSIONS: PA program for
lubiprostone offers no ﬁnancial savings to a Medicare plan based
on current approval rates and annual utilization for elderly
patients with CC in the base case as well as in sensitivity analyses.
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OBJECTIVE: To examine pharmacy costs of a Prior Authoriza-
tion (PA) restriction on lubiprostone for chronic constipation
(CC) patients in a commercial managed care plan. METHODS:
Cost impact of PA was calculated by estimating annual pharmacy
cost differences with PA (medication costs + PA administration)
and without PA (medication costs only). Model inputs included
CC prevalence estimates from the literature; lubiprostone utili-
zation from IMS Health, 2007; average PA approval rate, PA
costs and co-payment from managed care interviews; and lubi-
prostone wholesale acquisition costs. Annual medication costs in
both scenarios included costs and utilization of lubiprostone less
co-payment, assuming third-tier placement for lubiprostone. All
previously rejected prescriptions were assumed to be accepted
after lifting PA, resulting in 11.36% increase in prescription
volume. Sensitivity analyses were performed on cost per PA, PA
approval rate, and expected increase in prescription volume
after lifting PA. RESULTS: CC prevalence was 14.7%, of which
1.14% were lubiprostone users. For a 1-million member plan,
this resulted in 1264 PA requests costing $27 each. Annual cost
of PA administration was $34,130. PA acceptance rate was
81.90% (or 1035 approved users). Average number of ﬁlls per
person per year was 3.8. A 30-day lubiprostone prescription
costed $43.40 ($86.40 WAC-$45 co-payment + $2 dispensing
fee). Drug costs were $170,737, resulting in total annual cost
with PA of $204,867. Total costs without PA were $190,125,
based on additional 118 approved users, resulting in annual
savings of $14,742. Sensitivity analyses indicated break even
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